XENE Xenon Pharmaceuticals Inc.

8-K Current Report

Filed: February 27, 2026

Health Care

Pharmaceutical Preparations

Xenon Pharmaceuticals Inc. (XENE) 8-K current report filed with SEC EDGAR on February 27, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• ATM program refreshed with $400M capacity via new prospectus supplement filed Feb 27, 2026, superseding prior prospectus
• Already sold $291M under existing Sales Agreement, leaving meaningful remaining capacity under the new $400M shelf

+2 more insights

Other Xenon Pharmaceuticals Inc. 8-K Filings

Get deeper insights on Xenon Pharmaceuticals Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.